An open-label, multicenter, phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer after prior platinum containing first line chemotherapy.

Trial Profile

An open-label, multicenter, phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer after prior platinum containing first line chemotherapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2010

At a glance

  • Drugs AT 101; Topotecan
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Ascenta Therapeutics
  • Most Recent Events

    • 23 Jun 2009 Results presented at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, according to an Ascenta media release.
    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 May 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top